PANORAMA DU M�DECIN 2009-06-01

[Drug treatment for hypertrophic cardiomyopathy].

Pierre Gibelin

Index: Presse Med. 38(6) , 1001-4, (2009)

Full Text: HTML

Abstract

Drug treatment of hypertrophic cardiomyopathy is the first-line treatment, at the onset of clinical signs and symptoms. Beta-blockers are proposed for symptomatic patients with no gradient or with a gradient that appears only on exertion. Verapamil is the standard second-line drug,when the beta-blockers are insufficient or ineffective but must be avoided when there is blockage at rest with severe symptoms. Disopyramide is indicated for patients with obstruction who do not respond to beta blockers and/or verapamil. Treatment with anticoagulants is widely prescribed because this disease is highly emboligenic.

Related Compounds

  • Disopyramid phosph...

Related Articles:

A review of the effects of disopyramide phosphate on left ventricular function and the peripheral circulation.

1987-02-01

[Angiology 38(2 Pt 2) , 174-83, (1987)]

[Disopyramide phosphate: the electrophysiological mechanisms of its anti-arrhythmia action and its use in clinical practice].

1985-05-01

[Kardiologiia 25(5) , 114-8, (1985)]

Disopyramide-induced hypoglycemia in a non-diabetic hemodialysis patient: a case report and review of the literature.

2011-11-01

[Clin. Nephrol. 76(5) , 401-6, (2011)]

A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy.

2012-01-01

[Prog. Cardiovasc. Dis. 54(6) , 483-92, (2012)]

Monitoring disopyramide, lidocaine, and quinidine by micellar liquid chromatography.

2011-01-01

[J. AOAC Int. 94(2) , 537-42, (2011)]

More Articles...